CU Medical Systems, Inc.

As of March 31, 2026, CU Medical Systems, Inc. carries a market capitalization of 29.84B, placing it among publicly traded companies globally. Its enterprise value stands at 63.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, CU Medical Systems, Inc. has 12.10M shares outstanding.

As of March 31, 2026, CU Medical Systems, Inc. trades at a trailing price-to-earnings ratio of 9.37. The price-to-sales ratio is 0.55, and the price-to-book ratio stands at 0.48.

As of March 31, 2026, CU Medical Systems, Inc. trades at an EV/EBITDA multiple of 4.09 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.17 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.23 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. CU Medical Systems, Inc. trades at an EV/FCF ratio of 4.56, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 63.80B versus a market cap of 29.84B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, CU Medical Systems, Inc. maintains a current ratio of 1.95, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 63.62, indicating elevated leverage, while an interest coverage ratio of 10.78 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, CU Medical Systems, Inc. posted a return on equity (ROE) of 5.22, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.27 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.68, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.20, useful for judging operating efficiency across full business cycles. The company generates approximately 469.22M in revenue per employee across its workforce of 116.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.70 indicates how many times CU Medical Systems, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, CU Medical Systems, Inc. recorded 726.17M in income tax expense. That works out to an effective tax rate of 19.57, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 3.71B, leaving 3.18B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, CU Medical Systems, Inc.'s stock has declined approximately 33.77% over the past 52 weeks. The 50-day moving average sits at 2,226.08, while the 200-day moving average is 2,399.88.

Over the twelve months ended March 31, 2026, CU Medical Systems, Inc. generated 54.66B in revenue and converted that into 3.18B in net income, yielding earnings per share of 233.81. EBITDA reached 15.60B, while operating income came in at 12.45B.

As of March 31, 2026, CU Medical Systems, Inc. holds 24.63B in cash and equivalents against 46.94B in total debt, resulting in a net debt position of 23.17B. Total book value stands at 62.15B, with working capital of 28.73B providing operational flexibility.

CU Medical Systems, Inc. produced 13.36B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -532.33M in capital expenditures, free cash flow totaled 12.82B - equivalent to 1,059.39 per share.

Over the twelve months ended March 31, 2026, CU Medical Systems, Inc. posted a gross margin of 57.56, reflecting its pricing power and cost economics. The operating margin of 22.78 and net profit margin of 5.83 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 40.77, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -39.57, meaning CU Medical Systems, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

CU Medical Systems, Inc.'s most recent stock split took place on May 20, 2026 with a 5:1 split ratio.

As of March 31, 2026, CU Medical Systems, Inc. has an Altman Z-Score of 1.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.